Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates

Author's Avatar
Nov 08, 2022

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2022.